Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 5/20 | 0.60 |
| ▸ | KIT | P10721 | 3/20 | 0.60 |
| ▸ | KDR | P35968 | 1/20 | 0.60 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.58 |
| ▸ | ACHE | P22303 | 5/20 | 0.57 |
| ▸ | BACE1 | P56817 | 5/20 | 0.57 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 10/20 | 0.56 |
| ▸ | FLT3 | P36888 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4966363 | 0.95 | PDGFRA (0.56) | PDGFRAKITKDRENPP1ACHE | |
| SCHEMBL4967916 | 0.94 | PDGFRA (0.57) | PDGFRAKITKDRENPP1ACHE | |
| SCHEMBL4969305 | 0.93 | PDE10A (0.61) | PDGFRAKITKDRENPP1ACHE | |
| SCHEMBL4966150 | 0.89 | PDGFRB (0.70) | PDGFRAKITKDRENPP1ACHE | |
| SCHEMBL4969927 | 0.89 | ENPP1 (0.55) | PDGFRAKITKDRENPP1ACHE | |
| SCHEMBL4965465 | 0.88 | PDE10A (0.57) | PDGFRAKITKDRENPP1ACHE | |
| SCHEMBL4966832 | 0.87 | PDGFRB (0.71) | PDGFRAKITKDRENPP1PAK1 | |
| SCHEMBL4966896 | 0.87 | PDGFRA (0.57) | PDGFRAKITKDRENPP1PAK1 | |
| SCHEMBL4974993 | 0.87 | PDGFRA (0.64) | PDGFRAKITKDRPAK1PDGFRB | |
| SCHEMBL4965855 | 0.86 | PDGFRB (0.72) | PDGFRAKITKDRPAK1PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1899319-A2 | AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-19 | — | — | EP | disclosed |
| EP-1893206-A2 | SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-05 | — | — | EP | disclosed |
| US-20070004763-A1 | AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-04 | — | — | US | disclosed |
| US-20070004763-A1 | AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-04 | — | — | US | disclosed |
| US-20070004763-A1 | AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-04 | — | — | US | disclosed |
| WO-2006135649-A2 | AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006135636-A2 | SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | WO | disclosed |
| US-20060281771-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281771-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | FLT3, CDC42BPG, PRKCQ | PDGFRA 460/4885KIT 197/4885KDR 483/4885 |
| US-20070004763-A1 | AMINOQUINOLINE AND AMINOQUINAZOLINE KINASE MODULATORS | FLT3, BMX, ABL1 | PDGFRA 74/4885KIT 104/4885KDR 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.